Alnylam Pharmaceuticals Stock Price Prediction

ALNY Stock  USD 152.33  2.02  1.34%   
At this time, the RSI of Alnylam Pharmaceuticals' share price is approaching 35. This suggests that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Alnylam Pharmaceuticals, making its price go up or down.

Oversold Vs Overbought

35

 
Oversold
 
Overbought
Alnylam Pharmaceuticals stock price prediction is an act of determining the future value of Alnylam Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Alnylam Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Alnylam Pharmaceuticals and does not consider all of the tangible or intangible factors available from Alnylam Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Alnylam Pharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Alnylam Pharmaceuticals' stock price prediction:
EPS Estimate Next Quarter
(1.04)
EPS Estimate Current Year
(4.11)
EPS Estimate Next Year
(1.76)
Wall Street Target Price
222.41
EPS Estimate Current Quarter
(1.18)
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Alnylam Pharmaceuticals based on different types of headlines from major news networks to social media. The Alnylam stock price prediction module provides an analysis of price elasticity to changes in media outlook on Alnylam Pharmaceuticals over a specific investment horizon. Using Alnylam Pharmaceuticals hype-based prediction, you can estimate the value of Alnylam Pharmaceuticals from the perspective of Alnylam Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Alnylam Pharmaceuticals using Alnylam Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Alnylam using crowd psychology based on the activity and movement of Alnylam Pharmaceuticals' stock price.

Alnylam Pharmaceuticals Short Interest

A significant increase or decrease in Alnylam Pharmaceuticals' short interest from the previous month could be a good indicator of investor sentiment towards Alnylam. Short interest can provide insight into the potential direction of Alnylam Pharmaceuticals stock and how bullish or bearish investors feel about the market overall. An investor who is long Alnylam Pharmaceuticals may also wish to track short interest. As short interest increases, investors should be becoming more worried about Alnylam Pharmaceuticals and may potentially protect profits, hedge Alnylam Pharmaceuticals with its derivative instruments, or be ready for some potential downside.
200 Day MA
171.9455
Short Percent
0.0228
Short Ratio
4.49
Shares Short Prior Month
2.8 M
50 Day MA
150.1168

Alnylam Pharmaceuticals Hype to Price Pattern

Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Alnylam Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals Implied Volatility

    
  35.49  
Alnylam Pharmaceuticals' implied volatility exposes the market's sentiment of Alnylam Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Alnylam Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Alnylam Pharmaceuticals stock will not fluctuate a lot when Alnylam Pharmaceuticals' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Alnylam Pharmaceuticals. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Alnylam Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Alnylam because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Alnylam Pharmaceuticals after-hype prediction price

    
  USD 152.39  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.

Prediction based on Rule 16 of the current Alnylam contract

Based on the Rule 16, the options market is currently suggesting that Alnylam Pharmaceuticals will have an average daily up or down price movement of about 2.22% per day over the life of the 2024-05-17 option contract. With Alnylam Pharmaceuticals trading at USD 152.33, that is roughly USD 3.38 . If you think that the market is fully incorporating Alnylam Pharmaceuticals' daily price movement you should consider acquiring Alnylam Pharmaceuticals options at the current volatility level of 35.49%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Check out Alnylam Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Alnylam Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
137.10181.91184.09
Details
Naive
Forecast
LowNextHigh
154.10156.28158.45
Details
30 Analysts
Consensus
LowTargetHigh
208.74229.39254.62
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.56-1.18-0.27
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Alnylam Pharmaceuticals. Your research has to be compared to or analyzed against Alnylam Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Alnylam Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Alnylam Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Alnylam Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Alnylam Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Alnylam Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Alnylam Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Alnylam Pharmaceuticals' historical news coverage. Alnylam Pharmaceuticals' after-hype downside and upside margins for the prediction period are 150.21 and 154.57, respectively. We have considered Alnylam Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
152.33
150.21
Downside
152.39
After-hype Price
154.57
Upside
Alnylam Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Alnylam Pharmaceuticals is based on 3 months time horizon.

Alnylam Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Alnylam Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alnylam Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Alnylam Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.16 
2.18
  0.06 
  0.08 
9 Events / Month
14 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
152.33
152.39
0.04 
622.86  
Notes

Alnylam Pharmaceuticals Hype Timeline

Alnylam Pharmaceuticals is presently traded for 152.33. The entity has historical hype elasticity of 0.06, and average elasticity to hype of competition of -0.08. Alnylam is estimated to increase in value after the next headline, with the price projected to jump to 152.39 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 0.04%, whereas the daily expected return is presently at -0.16%. The volatility of related hype on Alnylam Pharmaceuticals is about 421.14%, with the expected price after the next announcement by competition of 152.25. The company reported the previous year's revenue of 1.83 B. Net Loss for the year was (440.24 M) with profit before overhead, payroll, taxes, and interest of 868.6 M. Given the investment horizon of 90 days the next estimated press release will be in about 9 days.
Check out Alnylam Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Alnylam Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Alnylam Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Alnylam Pharmaceuticals' future price movements. Getting to know how Alnylam Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Alnylam Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
PRQRProQR Therapeutics BV(0.03)6 per month 0.00 (0.03) 6.99 (5.44) 20.48 
WVEWave Life Sciences(0.18)8 per month 4.35  0.1  8.43 (8.36) 44.08 
BPMCBlueprint Medicines Corp(0.79)10 per month 2.86  0.11  5.71 (4.78) 19.44 
APLSApellis Pharmaceuticals 3.13 13 per month 0.00 (0.16) 4.21 (7.07) 16.59 
INCYIncyte 0.09 10 per month 0.00 (0.16) 1.87 (2.40) 6.54 
UTHRUnited Therapeutics(2.74)8 per month 1.30  0.13  2.78 (1.95) 9.90 
RAREUltragenyx(0.89)7 per month 0.00 (0.04) 4.25 (4.00) 15.57 
BMRNBiomarin Pharmaceutical 0.49 11 per month 0.00 (0.08) 2.37 (2.32) 12.77 
SGENSeagen Inc(0.31)8 per month 0.17  0.12  1.20 (0.63) 5.21 
EXELExelixis 0.27 12 per month 2.20 (0.01) 1.84 (1.99) 10.48 
HALOHalozyme Therapeutics 0.06 12 per month 1.17  0.12  3.37 (2.15) 9.38 
KRYSKrystal Biotech 2.31 12 per month 2.18  0.1  5.24 (4.19) 45.71 
MDGLMadrigal Pharmaceuticals(10.29)9 per month 4.67  0.01  8.89 (7.09) 24.70 
RETAReata Pharmaceuticals(0.25)7 per month 0.38  0.15  3.54 (2.91) 54.98 
ISEEIVERIC Bio(0.03)10 per month 0.25  0.26  2.45 (1.52) 18.29 
AMLXAmylyx Pharmaceuticals(0.02)9 per month 0.00 (0.15) 7.95 (8.30) 103.39 
DAWNDay One Biopharmaceuticals 0.38 11 per month 4.33  0.07  8.19 (8.71) 24.09 

Alnylam Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Alnylam price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Alnylam using various technical indicators. When you analyze Alnylam charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Alnylam Pharmaceuticals Predictive Indicators

The successful prediction of Alnylam Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Alnylam Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Alnylam Pharmaceuticals based on analysis of Alnylam Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Alnylam Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Alnylam Pharmaceuticals's related companies.
 2021 2022 2023 2024 (projected)
Payables Turnover1.911.725.595.87
Days Of Inventory On Hand319.57278.83104.8299.58

Story Coverage note for Alnylam Pharmaceuticals

The number of cover stories for Alnylam Pharmaceuticals depends on current market conditions and Alnylam Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Alnylam Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Alnylam Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Alnylam Pharmaceuticals Short Properties

Alnylam Pharmaceuticals' future price predictability will typically decrease when Alnylam Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Alnylam Pharmaceuticals often depends not only on the future outlook of the potential Alnylam Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Alnylam Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding124.9 M
Cash And Short Term Investments2.4 B
When determining whether Alnylam Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alnylam Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alnylam Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alnylam Pharmaceuticals Stock:
Check out Alnylam Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Alnylam Stock analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.52)
Revenue Per Share
14.637
Quarterly Revenue Growth
0.312
Return On Assets
(0.05)
Return On Equity
(15.01)
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.